BREAKING: Tech Futures Jump On Megacap Earnings Biogen stock popped on a single July day after the biotech company asked the Food and Drug Administration to approve its controversial Alzheimer's treatment.In June, a District Court judge in West Virginia invalidated a patent protecting Biogen's biggest moneymaker, multiple sclerosis drug Tecfidera, from the generic rival.